SkinBioTherapeutics
SkinBioTherapeutics is a biotechnology company developing microbiome-based technologies for skin health.
Its proprietary platform harnesses lysates derived from probiotic bacteria to improve skin barrier function, reduce infection risk, and support wound healing.
Programmes target cosmetic skincare, psoriasis, eczema, and infection control markets, with a commercial partnership with Croda International for cosmetic ingredient development.
The food supplement for psoriasis is commercially available across multiple markets.
Latest News
SkinBioTherapeutics Confirms Rachel Parsonage as CEO and Alyson Levett as Chair
SkinBioTherapeutics has appointed Rachel Parsonage as permanent Chief Executive and Alyson Levett as permanent Non-Executive Chair, having held both roles on an interim basis. Parsonage joined in March 2026 and Levett in June, following an investigation into the conduct of the former chief executive.
SkinBioTherapeutics Appoints Anita Slater as Interim CFO
SkinBioTherapeutics has appointed Anita Slater as interim Chief Financial Officer for an initial six-month term, effective immediately. Slater is a chartered accountant with around 30 years of commercial and financial leadership experience across AIM-listed and FTSE top 10 companies, and joins as the group continues to strengthen its governance and financial controls.